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 Abstract (350 words) 
 
 
Purpose: There is a lack of a valid, definition for skin ulcers in SSc  to be used in clinical 
trials. Our aim was to develop a consensus definition for SSc-skin ulcers based on the 
results of a systematic literature review (SLR) for skin ulcer definitions and expert opinion; 
and to evaluate its face validity, reproducibility and feasibility. 
 
Methods: 
SLR for skin ulcer definitions was conducted using PubMed, Web of Science, and 
Cochrane library for articles published from inception to January 1st, 2016. SSc experts 
were to discuss the definitions’ categories and vote for the relevant terms. Reproducibility 
of the definition were tested in a second expert meeting, seven SSc experts evaluated 7 
SSc pts with skin lesions twice. Face validity and feasibility evaluated by sending out case 
report forms(CRFs) to 4 SSc experts, they were asked to use the definition in 5 pts each. 
 
Results: A total of 3464 abstracts and titles were screened, and 446 articles were fully 
evaluated. Of these, 66 met eligibility criteria and skin ulcer definitions were extracted. SSc 
experts discussed, refined and voted on the consensus definition using nominal process. 
Kappa for inter-, intra-rater rater agreement was 0.51, 0.90 respectively. The mean time to 
decide if the lesion is an ulcer was 7.4 sec. All investigators endorsed the face validity of 
the new definition in the CRFs. 
 
Conclusion: Using a SLR and a nominal technique, we developed a preliminary 
consensus-based definition of SSc-skin ulcers. Face validity, feasibility and reproducibility 
were demonstrated for the developed definition.  
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Introduction 
              Systemic sclerosis (SSc) is an immune mediated disease with multiple phenotypic 
presentations, driven by interplay of autoimmunity and vasculopathy leading to dermal and 
internal organ fibrosis. In SSc, skin ulcers are a major challenge usually secondary to 
vasculopathy and less frequently to  trauma, calcinosis or gangrene (1-3). Skin ulcers are 
frequently found on finger tips, on toes or over the extensor surfaces and bony 
prominences (such as the elbow) (3). Most ulcers are painful and often result in 
considerable impairment of hand function (4). Digital ulcers (DU) tend to recur, with up to 
66% of patients having more than one episode, despite use of vasodilators (5). 
Additionally, there is a risk of subsequent irreversible tissue loss, as well as other 
significant complications including osteomyelitis, gangrene, and amputation (3).  It is 
estimated that up to 5-10% of SSc patients experience gangrene or amputation (6-9). The 
risk of gangrene and amputation rises to 20% in patients with DUs while the incidence of 
amputation ranges from 1 to 2% of patients/year (10, 11). Patients with DU show 
significantly disability characterized by impaired hand function, increased pain and altered 
quality of life (QOL) (12). In SSc, DU are also a considerable financial burden, as patients 
require more hospitalizations (including cost of antibiotics) than those without DU. (12,13). 
There are a variety of indicators for assessing DU, in particular their severity, like ulcer 
size, number, location, loss of function, pain, infection and evolution to gangrene. It has 
been shown that the origin of the DU dictates the time to healing (3) and that usually an 
infected DU needs more time to heal.    
Given the effect of DU on QOL and hand function, a valid and reliable definition of a SSc 
ulcer is an unmet need. This may impact whether the clinical trials are to be designed to 
favour prevention or healing of DU. Despite DU prevention and healing being primary 
endpoints of clinical trials (19,21), there has been a difficulty to define by the physician 
what is precisely a SSc ulcer,  
With support from the World Scleroderma Foundation (WSF), we had the mission of 
developing a new consensus based definition for the purposes of clinical trials and to 
pursue its validation. 
As the first step in developing such a definition, we evaluated the definitions of “skin ulcer 
“in the literature. The primary aim of the present work was to develop a consensus based 
definition of ulcers in SSc, using the descriptive terms stated in the literature. The 
developed definition will then be further subjected to validation processes. 
 
 
Methods 
Literature search  
Since we anticipated a paucity of reported definitions and/or classification of ulcers in SSc, 
we included other related autoimmune diseases (systemic lupus erythematosus (SLE), 
rheumatoid arthritis (RA) and vasculitis) in our search. Diabetic ulcers are also of interest 
because there has been much effort regarding defining skin ulcers in diabetes. Pressure 
ulcers were excluded because their pathogenesis is varied and often unrelated to the 
pathogenesis of SSc- related ulcers. We conducted a systematic literature review (SLR) 
examining the clinical studies reporting a definition of skin ulcers in SSc, in autoimmune 
diseases (SLE, RA, vasculitis), and in diabetes mellitus. 
Data Sources: Database searches were carried out by two investigators (DEF, YS) and a 
library information specialist(B.M.). PubMed, Web of Science, and Cochrane database 
were searched for articles published from inception to January 1st, 2016. The search was 
limited to English language.  
Search terms: : Keywords and MeSH terms for the following concepts were used in the 
search: skin ulcer, nonhealing wound, or chronic wound; scleroderma, systemic sclerosis, 
systemic lupus erythematosus, rheumatoid arthrisis, vasculitis, or diabetes; classification 
or definition; and clinical trials. 
 
Study selection 
Studies satisfying the following Inclusion criteria were selected for full data abstraction: 
1) peer reviewed studies in SSc, SLE, RA, vasculitis and/or diabetes mellitus, 2) reporting 
skin ulcers as an outcome, 3) in 10 or more patients, 4) adults (age ≥18 years). 
Exclusion criteria were: 1) not in humans (e.g. genetic basic research or mice); 2) not in 
disease(s) of interest; 3) not in body areas of interest such as oral ulcers, nasal ulcers, 
gastro-intestinal ulcer and not associated with the pathogenesis of skin ulcers, 4) pressure 
ulcer; 5) review articles; 6) skin ulcer is not outcome ; 7) duplicate publication; 8) case 
reports/case series with <10 patients; 9) patients <  8 years of age. 
 
Data abstraction  
Three groups of investigators (YS, MA, NB, EP, CB and LC) with two investigators per 
group, each independently reviewed the title and abstract of each citation and applied the 
inclusion and exclusion criteria to select studies for full review. A standardized data 
abstraction form was used. Cross-review of 10% of studies among reviewers established 
consistency of review. If there was disagreement, consensus was reached among the 2 
reviewers by discussion. If necessary, a third reviewer (DEF) arbitrated. 
 
Outcomes 
The primary outcome was skin ulcer definitions reported in the publication. The secondary 
outcome was the classification systems for subsetting the ulcers to develop a “grading 
system” of skin ulcers in SSc. During the above extraction process, those terms which are 
not part of the definition were extracted. 
Definition Formulation 
In a face-to-face meeting, SSc experts from North America (n=6) and Europe (n=6) 
participated in developing the new SSc definition. Extracted definitions and descriptive 
terms were categorized into domains according to the defective skin layers, depth 
description and mitigating factors (size, site, calcinosis, pain, etc.) Unclear or non-specific 
definitions were excluded from inclusion in our voting process. SSc experts discussed the 
definitions using a nominal process and voted for the pertinent definition terms during the 
Scleroderma World Congress  2016 held in Lisbon, Portugal. Nominal group 
technique(NGT) was utilized,  whenever there was disagreements, discussion ensued with 
possible further refinement until consensus was achieved. A consensus was defined as 
>70% agreement among participants. Photographs of 11 SSc skin lesions were evaluated 
before and after definition development to examine the face validity of the definition and to 
allow further refinement of the definition. 
 
Reliability 
A second face to face meeting was conducted at the Royal Free Hospital (London, UK) to 
evaluate reliability, and feasibility of the newly developed definition: 7 rheumatologists 
discussed and refined the developed definition.  Each investigator assessed 7 SSc 
patients with skin lesions twice. Each patient was identified through her/his initials and was 
sitting on a chair in front of a table marked with a number, with 7 separate tables placed in 
the same room with a circular disposition. Each clinician was given a 30 seconds time to 
sit in front of the patient and decide if the definition suited the patient lesion, then moving 
to the next table counterclockwise. After the first round was concluded, all clinicians moved 
to a second room. While a nurse prepared patients for the second round using an online 
available randomizing software (www.random.org) to change patients’ order. The second 
round was repeated as above. 
 
Feasibility and Face validity: 
Photographs of 11 SSc skin lesions were evaluated before and after definition 
development to examine the face validity and feasibility of the definition and to allow 
further refinement of the definition 
Case report forms containing the newly developed definition were sent to four investigators 
to use the new definition in assessment of skin lesions and evaluate if they found it 
credible and ascertained the time (in seconds) taken to decide if the skin lesion is an ulcer 
or not.  
 
Analysis 
Descriptive statistics were used to summarize the data. The results adhere to the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines for systematic literature reviews and meta-analyses (14). Inter-rater agreement 
was evaluated for each separate round using Fleiss' Kappa, while intra-rater agreement 
was evaluated using Cohen's Kappa statistic. Stength of agreement was interpreted as 
follows: 0 = poor, 0.01–0.20 = slight, 0.21–0.40 = fair, 0.41–0.60 = moderate, 0.61–0.80 = 
substantial, and 0.81–1 = almost perfect. 
Results 
Systematic literature review driven definitions  
Database searches yielded 3464 publications. After removing duplicates (n= 251), 3213 
titles and abstracts were screened, resulting in 446 articles with data referring to skin 
ulcers as an outcome for full text review (Fig. 1). Sixty-three abstracts were case reports, 
1373 abstracts reported diseases not of interest, 38 studies were juvenile cases and 675 
abstracts did not report skin ulcer as an outcome. Skin ulcer definitions were extracted 
from 66 studies, after consensus by the 2 investigators in each group. Definitions were 
extracted from 34 SSc studies, 28 diabetes and 4 rheumatoid arthritis articles.   
Supplementary Table 1 showing extracted definitions (supplementary). 
 
 
Formulation of a new Definition 
The results of the literature search were reviewed and a list of domains were developed to 
group descriptive terms. The domains (e.g. loss of epidermis) are listed in table 1. The 
potentially important mitigating factors (e.g. site, size, etc.) were also considered and are 
listed in table 2.  
At the first face-to-face meeting, the domains and mitigating factors were presented to the 
SSc experts (11 rheumatologists, 1 dermatologist), and voting on inclusion and exclusion 
of each domain or factor ensued. The final definition was developed by consensus using 
NGT for utilization in clinical trials. 
 
The proposed WSF definition was developed as follows: “Loss of epidermal covering with 
a break in the basement membrane (which separates dermis from epidermis). It appears 
clinically as visible blood vessels, fibrin, granulation tissue and/or underlying deeper 
structures (e.g. muscle, ligament, fat) or as it would appear on debridement" Definition 
and exclusions are in box.1 
 
Validation of the new definition 
Face validity (15) was shown by applying the newly developed definition to photographs of 
11 SSc skin lesions after consensus definition development by SSc experts. Further 
intensive discussions took place during the 2nd F2F meeting resulted in modification of the 
definition for inclusion in a clinical trial, the main item for discussion was the need for 
debridement to be able to fully  asses an ulcer (if covered by an eschar), with resultant 
addition of the sentence   ‘’as it would appear on debridement’’(4th line in the definition in 
italic see Box 1).  
 
Reliability of the newly developed definition between and within raters was then tested in 
the 2nd face-to-face meeting. The Kappa for inter-rater agreement during was 0.51 and 
during round two was 0.49. The mean intra-rater Cohen's Kappa is 0.90.  
Feasibility was evaluated by examining the time taken to apply the definition in a clinical 
setting, where 20 patients with SSc related skin lesions were examined by 4 
investigators.It took a mean of 7.4 (3-20) seconds for each investigator to apply the 
definition. 
 
Discussion 
In SSc,  studies  of skin ulcer treatment  in systemic sclerosis frequently do not show 
treatment effects or showed  variable or unclear results (16,18).It is quite possible that 
unclear or inconsistent definitions of the ulcer contributed to these poor or unclear results. 
Our study has systematically started to define an ulcer in SSc and has also started the 
process of validating such a definition. We conducted a systematic literature review to 
identify published definitions of ‘skin ulcers’ in the literature. The resulting definitions were 
then categorized into definitions domains and were voted upon by the co-authors using a 
modified nominal group technique to develop a consensus-based definition of SSc-skin 
ulcers. Face validity, reliability and feasibility of the new SSc skin ulcer definition were 
evaluated. The intra-rater reliability was excellent, while inter-rater reproducibility was 
moderate. This points to the need to have the same evaluator measuring ulcers for each 
patient, as is also required for trials of rheumatoid arthritis(17). We wanted to ensure a 
certain degree of uniformity among included SSc-skin ulcers in clinical trials by excluding 
factors that might confound the inclusion decision and the resultant treatment effect (e.g. 
calcinosis, infection), hence promote better precision among included SSc-skin ulcers. 
 
The development of the exclusion list started during the extraction process, in addition to 
extensive discussions during the electronic search process. The presence of an expert 
dermatologist among the SSc experts provided for a further refinement of the definition 
development process. Histologic explanation of skin layers and the difference between 
erosion (abrasion) and skin ulcer were discussed. The skin ulcers overlying calcinosis 
were considered traumatic and excluded. The issue of whether infected skin ulcers were to 
be allowed when defining SSc-skin ulcers in clinical trials was considered and their 
presence was agreed to be an exclusion for trial inclusion.  
 
Another significant aspect in the definition is the phrase “or as it would appear on 
debridement “. This is clearly of importance since some SSc-skin ulcers are covered with a 
scab or eschar, as was discovered during the reliability exercises. This points to an area 
requiring further research and will need to be addressed when ulcer studies are designed 
Wound bed preparation and debridement are thus helpful to allow the assessment of the 
underlying ulcer and evaluate if it meets the definition (19). An important unresolved issue 
whether or not to require debridement of each included ulcer in a clinical trial.  It was 
agreed that this aspect of DU definition can be decided at the time the trial is designed. 
 
Our systematic literature review highlighted the lack of uniformity for SSc-skin ulcer 
definition and facilitated the development of the domains from the published definitions.  
The study by Baron et al., classified SSc-skin ulcers into three categories: active, healed 
and indeterminate for the purpose of clinical trials (20). Their definition was included as 
one of the significant definitions extracted. The study by Baron et al., classified SSc-skin 
ulcers into three categories: active, healed and indeterminate for the purpose of clinical 
trials(20). Their definition was included as one of the significant definitions extracted. Their  
definition of ‘active’, “inactive” and “indeterminate” , were defined in the manuscript;  
nevertheless  there are difficulties with these definitions. For example,  “active” implies an 
ulcer can exist but be “inactive” and many believe, quite reasonably, that an “inactive” 
ulcer is no longer an ulcer at all. Likewise, “ indeterminate”  seems to indicate that the 
observer is not quite sure whether there is an ulcer or not. This status, as “indeterminate”  
can lead to greater variability and , hence, less ability to come to a clear result. This issue  
may be clarified, for example, by debridement or use of ultra-sound but will require further 
clarification.. 
 
A recent study by Hughes et al, 2016, evaluated  whether the reliability among  
rheumatologists grading DUs improves by providing the assessor with clinical information. 
They used 80 images and 51 rheumatologists (web based), change in intrarater (0.64- 
0.71),  inter-rater (0.32-0.36) reliability   was not significant . they concluded that the inter 
and intra rater reliability of DU grading did not improve  with  providing of pts clinical 
context (21). This study emphasize the need for a more uniform definition that is widely 
acceptable and reliable 
 
An earlier study by Herrick et al, evaluated the inter- and intra-rater reliability among SSc 
experts, to assess their ability to define an active SSc-skin ulcer via SSc-skin ulcer images 
(22). Their overall intra-rater weighted kappa coefficient was 0.81, while the inter-rater 
kappa co-efficient was 0.46, generally similar to ours. They did not use a consensus 
definition; instead they used 13 exemplar lesions agreed upon by the clinicians who 
designed the study.  
Our study had the strengths of utilizing a literature–based systematic review to derive 
potential ulcer definitions, the advantage of having experts from both rheumatology and 
dermatology, the use of both experienced and less experienced experts (thus ensuring a 
more generalized representativeness), and the use  of a nominal technique to develop the 
consensus, thus assuring face validity. Further reliability and feasibility were directly 
measured. 
 
The limitations of our study included lack of direct input from patients, although, for clinical 
trial purposes this was not essential. In addition, content, construct, criterion validity and 
response/discrimination remain to be evaluated, although these psychometric properties 
were deliberately left for the future. Another limitation is the small number of pts used in 
our reliability study, although this number may be inadequate we believe this is sufficient in 
this early stage of validation. Larger numbers of ulcers are warranted in future studies. 
 
In conclusion, we used systematic literature review and nominal techniques to derive a 
consensus-definition of  skin ulcers in SSc. We demonstrated face validity, feasibility and 
reliability of the SSc-ulcer definition for clinical trials of interventions in SSc-skin ulcers. 
Other aspects of validation and responsiveness remain to be completed. 
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Definition categories  Number of times used 
Loss of Epidermis  11 
Loss of Epidermis and Dermis(full 
thickness)  
34 
With Depth  4 
Denuded  4 
Non-specific/unclear/healing definitions: 
Ischemic necrotic ulcer 
Open sore 
Loss of tissue 
Open wound 
Skin break 
Necrotic lesion 
27 
 
Table 1: showing terms used to define skin ulcers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mitigating/Clarifying factors   
Site (10 times): for DU (finger tip, distal digits, distal to DIP, distal to proximal 
interphalangeal digital crease, distal to PIP), for diabetes (malleoli, below knee) 
Size (8 times) :for SSc (at least 2 mm), diabetic (0.5 to 30 cm2 ) 
Calcinosis (6 times): either as an inclusion or exclusion in ulcer definition.  
Painful (4 times): used as part of the definition only in the  scleroderma ulcers 
Scab (1 time): part of the definition of an indeterminate ulcer ( hardened covering of 
dried secretions (as blood, plasma, or pus) that forms over an ulcer). 
Gangrene (1 time): as an exclusion 
Skin fissure (8 times): in SSc as exclusion 
Healing ulcer (22 times): in SSc  as inclusion (amenable to healing or definition of 
healing) 
In Diabetes, inclusion not healing in 30 days or definition of healing. 
Pitting scar (5 times):defined as[ pinhole sized depression with hyperkeratosis}and 
excluded. 
Pathogenesis(4 times): ischemic, traumatic( mechanical),infectious 
 
Table 2: showing mitigating factors that were used in skin ulcer description 
 
 
 
 
 
 
 
 Figure 1: showing the systematic review diagram. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BOX 1: Showing the World Scleroderma Foundation (WSF) Definition for SSc-skin ulcers to be 
used in clinical trials 
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